CAS: 499-06-9; 3,5-Dimethylbenzoic Acid

上下游产品

CAS号108-67-8 均三甲苯 | CAS号124-38-9 二氧化碳 | CAS号22445-41-6 3,5-二甲基-1-碘苯 | CAS号109-77-3 丙二腈 | CAS号64-18-6 甲酸 | CAS号108-38-3 间二甲苯 | CAS号201230-82-2 carbon monoxide | CAS号5692-35-3 3,5-二甲基苯胺 | CAS号77130-24-6 N-[2-[(3,5-dime... | CAS号5779-95-3 3,5-二甲基苯甲醛 | CAS号554-95-0 均苯三甲酸 | CAS号499-49-0 5-甲基间苯二酸 | CAS号5379-16-8 3,5-二甲基苯乙酮 | CAS号4105-92-4 1,3,5-苯三羧酸三乙酯 | CAS号64-18-6 甲酸 | CAS号64-19-7 冰醋酸 | CAS号198220-36-9 2-碘-3,5-二甲基苯甲酸 | CAS号108-38-3 间二甲苯 | CAS号124-38-9 二氧化碳

均三甲苯置于叔丁基过氧化氢,1-丁基-3-甲基咪唑溴盐体系中,用 水 作为反应溶剂,化学反应 12.0H,以70%的收率获得产物3,5-二甲基苯甲酸
参考文献:通过中继催化剂系统在温和条件下选择性氧化苄基ch键的 一种有效方法,可增强ni-Mof-74的催化活性†
标题:通过中继催化剂系统在温和条件下选择性氧化苄基ch键的 一种有效方法,可增强ni-Mof-74的催化活性†
摘要:尽管镍基材料在有机合成中表现出与钯相似的催化活性,但是在没有其他助催化剂的情况下惰性c-h键的选择性氧化仍然是一个尚未解决的难题.本文介绍了一种通过中继催化策略增强[bmim] Br增强ni-Mof-74的ni-Mof-74催化活性的方法,该方法对于苄基ch键的选择性氧化非常有效.值得注意的是,催化剂的循环利用和放大实验证明了该方案的实用性.该方法结合了mof和离子液体(il)的催化优势,并提供了一种通过廉价高效的ni基催化剂进行氧化反应的见解.
DOI:10.1039/c7Cc09602J

专利信息

专利号:US-8742028-B2
优先权日:2009-05-06
标 题:Solid support for Fmoc-solid phase synthesis of peptide acids
发明人：SRIVASTAVA KRIPA S; DAVIS MATTHEW R
权利人:SRIVASTAVA KRIPA S; DAVIS MATTHEW R; MALLINCKRODT LLC
摘要:The present invention provides a solid support for Fmoc-solid phase synthesis of peptides. In particular, the solid supports of the invention may be utilized to produce peptide acids.

专利号:WO-2023095077-A1
优先权日:2021-11-26
标题 :A process for the treatment of tail gases
发明人：LODHA DHANANJAY MAHENDRA
权利人:SHREE SULPHURICS PVT LTD
摘要:The present disclosure relates to a process for the treatment of tail gases. The process of the present disclosure is simple and environmentally friendly. The process of the present disclosure produces chlorosulfonic acid, which is a value-added reagent used in the synthesis of alkyl sulphates detergents, saccharin and the like. Further, the process of the present disclosure produces sulfuryl chloride, which is an important value added chlorinating agent in the organic synthesis/reactions.

专利号:US-6214987-B1
优先权日:1994-09-02
标 题 :Compositions for enzyme catalyzed template-independent formation of phosphodiester bonds using protected nucleotides
发明人：HIATT ANDREW C; ROSE FLOYD
权利人:HIATT ANDREW C; ROSE FLOYD D
摘要:A method for the stepwise creation of phosphodiester bonds between desired nucleosides resulting in the synthesis of polynucleotides having a predetermined nucleotide sequence by preparing an initiation substrate containing a free and unmodified 3'-hydroxyl group; attaching a mononucleotide selected according to the order of the predetermined nucleotide sequence to the 3'-hydroxyl of the initiating substrate in a solution containing a catalytic amount of an enzyme capable of catalyzing the 5' to 3' phosphodiester linkage of the 5'-phosphate of the mononucleotide to the 3'-hydroxyl of the initiating substrate, wherein the mononucleotide contains a protected 3'-hydroxyl group, whereby the protected mononucleotide is covalently linked to the initiating substrate and further additions are hindered by the 3'-hydroxyl protecting group. Methods in which a mononucleotide immobilized on a solid support is added to a free polynucleotide chain are also disclosed.

专利号:US-5872244-A
优先权日:1994-09-02
标 题:3' protected nucleotides for enzyme catalyzed template-independent creation of phosphodiester bonds
发明人：HIATT ANDREW C; ROSE FLOYD
权利人:HIATT ANDREW C; ROSE FLOYD D
摘要:A method for the stepwise creation of phosphodiester bonds between desired nucleosides resulting in the synthesis of polynucleotides having a predetermined nucleotide sequence by preparing an initiation substrate containing a free and unmodified 3'-hydroxyl group; attaching a mononucleotide selected according to the order of the predetermined nucleotide sequence to the 3'-hydroxyl of the initiating substrate in a solution containing a catalytic amount of an enzyme capable of catalyzing the 5' to 3' phosphodiester linkage of the 5'-phosphate of the mononucleotide to the 3'-hydroxyl of the initiating substrate, wherein the mononucleotide contains a protected 3'-hydroxyl group, whereby the protected mononucleotide is covalently linked to the initiating substrate and further additions are hindered by the 3'-hydroxyl protecting group. Methods in which a mononucleotide immobilized on a solid support is added to a free polynucleotide chain are also disclosed.

专利号:US-2004110228-A1
优先权日:2002-04-01
标 题:Combinatorial organic synthesis of unique biologically active compounds
发明人：MCALPINE SHELLI R; TAYLOR RACHEL E; BOLLA MEGAN L; SEGALL ANCA M
摘要:The invention provides a method for making a combinatorial library of cyclic compounds, such as Holliday junction-trapping compounds, comprising the steps of (a) obtaining a plurality of trimers according to the generic structure X 1- X 2- X 3 , wherein X 1 , X 2 and X 3 can be independently any naturally or nonnaturally occurring amino acids or peptidomimetics thereof; (b) optionally coupling a spacer S to the trimer at either end; (c) cyclizing two trimers or trimer-spacer conjugates in a head-to-tail orientation; thereby obtaining a combinatorial library of compounds, wherein the library does not include an unmodifed or naturally occurring Holliday Junction-trapping compounds. The invention additionally provides methods macrocyclic compounds that are synergimycin derivatives.

专利号:US-5354772-A
优先权日:1982-11-22
标 题:Indole analogs of mevalonolactone and derivatives thereof
发明人：KATHAWALA FAIZULLA G
权利人:SANDOZ PHARMACEUTICALS CORP
摘要:Compounds of the formula wherein one of R and Ro is and the other is primary or secondary C1-6alkyl not containing an asymmetric carbon atom, C3-6cycloalkyl or phenyl-(CH2)m-, wherein R4 is hydrogen, C1-3alkyl, n-butyl, i-butyl, t-butyl, C1-3alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R5 is hydrogen, C1-3alkyl, C1-3alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R5a is hydrogen, C1-2alkyl, C1-2alkoxy, fluoro or chloro, and m is 1, 2 or 3, with the provisos that both R5 and R5a must be hydrogen when R4 is hydrogen, R5a must be hydrogen when R5 is hydrogen, not more than one of R4 and R5 is trifluoromethyl, not more than one of R4 and R5 is phenoxy, and not more than one of R4 and R5 is benzyloxy, R2 is hydrogen, C1-3alkyl, n-butyl, i-butyl, t-butyl, C3-6cycloalkyl, C1-3alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, R3 is hydrogen, C1-3alkyl, C1-3alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy, with the provisos that R3 must be hydrogen when R2 is hydrogen, not more than one of R2 and R3 is trifluoromethyl, not more than one of R2 and R3 is phenoxy, and not more than one of R2 and R3 is benzyloxy, X is -(CH2)n- or -CH=CH-, wherein n is 0, 1, 2 or 3, and Z is wherein R6 is hydrogen or C1-3alkyl, and R7 is hydrogen, R7b or M, wherein R7b is a physiologically acceptable and hydrolyzable ester group, and M is a pharmaceutically acceptable cation, the use thereof for inhibiting cholesterol biosynthesis and lowering the blood cholesterol level, and therefore, in the treatment of hyperliopoproteinemia and atherosclerosis, pharmaceutical compositions comprising such compounds and processes for and intermediates in the synthesis of such compounds.